Iodine staining and p16 immunohistochemistry as a novel screening for secondary esophageal neoplasm after hematopoietic stem cell transplantation

Bone Marrow Transplant. 2018 Oct;53(10):1359-1363. doi: 10.1038/s41409-018-0197-2. Epub 2018 May 8.

Affiliations

¹ Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
² Department of Gastroenterology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
³ Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan. [email protected].

PMID: 29740179
DOI: 10.1038/s41409-018-0197-2

No abstract available

Publication types

Clinical Trial
Letter
Observational Study

MeSH terms

Adolescent
Adult
Biomarkers, Tumor / metabolism*
Child
Child, Preschool
Cyclin-Dependent Kinase Inhibitor p16 / metabolism*
Esophageal Neoplasms* / metabolism
Esophageal Neoplasms* / pathology
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunohistochemistry
Infant
Iodine / chemistry*
Male
Neoplasms, Second Primary* / metabolism
Prospective Studies
Staining and Labeling*

Substances

Biomarkers, Tumor
CDKN2A protein, human
Cyclin-Dependent Kinase Inhibitor p16
Iodine